



Investor Conference Call Notification

Brisbane, Australia, 2 August 2022 – ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, invites shareholders to join a conference call hosted by Dr Tony Keating, CEO and Managing Director on Wednesday, 3 August 2022 at 10:00am Australian Eastern Standard Time (AEST).

The purpose of this call is to discuss the quarterly activities report for the period ending 30 June 2022. Dr Keating will not discuss or take questions in relation to the scheme of arrangement pursuant to which it is proposed that Pfizer Australia Holdings Pty Limited (a wholly-owned subsidiary of Pfizer Inc) will acquire all of the issued shares of ResApp or the scheme booklet announced to ASX on 18 July 2021 and dispatched to shareholders on 20 July 2021.

Any questions regarding the scheme of arrangement or the scheme booklet will not be answered on this call and should instead be addressed to the Shareholder Information Line on 1300 620 649 (within Australia) or +61 3 9415 4326 (outside Australia), Monday to Friday between 8:30am and 5:00pm (AEST).

For further information relating to the scheme, ResApp shareholders should carefully read and consider the Scheme Booklet in its entirety including the materials accompanying it. We also encourage shareholders to visit the Scheme website at www.resappscheme.com.

Shareholders can pre-register for the conference call by following the link below. You will receive a calendar notification with dial-in details and a PIN to access the call.

<https://s1.c-conf.com/diamondpass/10023601-s319fm.html>

###

About ResApp Health Limited

ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease. ResApp's machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp's regulatory-approved and clinically validated products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test; SleepCheckRx, a prescription-only smartphone application that screens adults for moderate to severe sleep apnoea; and SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnoea. For more information, please visit www.resapphealth.com.au.

ResApp Health Limited ABN 51 094 468 318

Level 12, 100 Creek St, Brisbane QLD 4000 Australia

T +61 7 3724 0035 E info@resapphealth.com.au W www.resapphealth.com.au



Contacts

Dr Tony Keating
CEO and Managing Director
+61 430 180 659
tony@resapphealth.com.au

Mr Brian Leedman
Executive Director, Corporate Affairs
+61 412 281 780
brian@resapphealth.com.au

This ASX announcement was approved and authorised for release by the board of directors of ResApp Health.